Migraine Nasal Spray Market Size

  • Report ID: 4059
  • Published Date: Dec 24, 2024
  • Report Format: PDF, PPT

Migraine Nasal Spray Market Size

Migraine Nasal Spray Market size was valued at USD 536.33 million in 2024 and is likely to cross USD 1.26 billion by 2037, registering more than 6.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of migraine nasal spray is estimated at USD 567.33 million.

The market growth can be attributed to growing prevalence of migraine, backed by the increased stress, depression, sleep deprivation, and anxiety prevalent amongst the population. In fact, migraine is the third most common disease, and approximately 1 billion people suffer from migraine worldwide. Furthermore, scientists suggest that humans are facing extreme weather changes, which can aggravate their health, making diseases, such as, migraine a common phenomenon. According to the World Meteorological Organisation, [R1] the decade 2011-2020 was the warmest on record, and the year 2020 is among the three warmest years globally. The increasing adulteration in food, hormonal misbalance, and longer screen time are also major reasons behind the growing number of migraine patients. Scientists have also found that migraine is more pervasive in women owing to hormonal changes, as 8 out of 10 people with migraine are women. As the number of patients with migraine is increasing exponentially, people are seeking an efficient remedy to eradicate the excruciating pain, which is expected to expand the global migraine nasal spray market.


Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4059
  • Published Date: Dec 24, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of migraine nasal spray is estimated at USD 567.33 million.

Migraine Nasal Spray Market size was valued at USD 536.33 million in 2024 and is likely to cross USD 1.26 billion by 2037, registering more than 6.8% CAGR during the forecast period i.e., between 2025-2037.

North America industry is anticipated to hold largest revenue share by 2037, impelled by increasing cases of migraine, raising awareness, and developing health care infrastructure.

The major players in the market are Upsher-Smith Laboratories, AstraZeneca plc, GlaxoSmithKline plc, Cipla Inc, Dr. Reddy’s Laboratories Ltd, Assertio Therapeutics, Inc., and Impel Neuro Pharma. Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample